Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study
Article first published online: 2 SEP 2009
© 2009 The Authors. Journal compilation © 2009 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 68, Issue 6, pages 844–851, December 2009
How to Cite
Viner, R. M., Hsia, Y., Neubert, A. and Wong, I. C. K. (2009), Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. British Journal of Clinical Pharmacology, 68: 844–851. doi: 10.1111/j.1365-2125.2009.03528.x
- Issue published online: 27 NOV 2009
- Article first published online: 2 SEP 2009
- Received 2 February 2009 Accepted1 July 2009
- antiobesity drug;
- children and adolescents;
- general practice;
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• The antiobesity drugs sibutramine and orlistat are not licensed for use in children and adolescents in the UK or USA.
• Clinical trials suggest antiobesity drugs are effective and well-tolerated in obese adolescents.
WHAT THIS STUDY ADDS
• Prescribing of unlicensed antiobesity drugs in children and adolescents has increased significantly in the past 8 years.
• Most prescribed antiobesity drugs in children and adolescents are rapidly discontinued before patients can see clinical benefit, suggesting they are poorly tolerated or poorly efficacious.
AIMS The international childhood obesity epidemic has driven increased use of unlicensed antiobesity drugs, whose efficacy and safety are poorly studied in children and adolescents. We investigated the use of unlicensed antiobesity drugs (orlistat, sibutramine and rimonabant) in children and adolescents (0–18 years) in the UK.
METHODS Population-based prescribing data from the UK General Practice Research Database between 1 January 1999 and 31 December 2006.
RESULTS A total of 452 subjects received 1334 prescriptions during the study period. The annual prevalence of antiobesity drug prescriptions rose significantly from 0.006 per 1000 [95% confidence interval (CI) 0.0007, 0.0113] in 1999 to 0.091 per 1000 (95% CI 0.07, 0.11) in 2006, a 15-fold increase, with similar increases seen in both genders. The majority of prescriptions were made to those ≥14 years old, although 25 prescriptions were made for children <12 years old. Orlistat accounted for 78.4% of all prescriptions; only one patient was prescribed rimonabant. However, approximately 45% of the patients ceased orlistat and 25% ceased sibutramine after only 1 month. The estimated mean treatment durations for orlistat and sibutramine were 3 and 4 months, respectively.
CONCLUSIONS Prescribing of unlicensed antiobesity drugs in children and adolescents has dramatically increased in the past 8 years. The majority are rapidly discontinued before patients can see weight benefit, suggesting they are poorly tolerated or poorly efficacious when used in the general population. Further research into the effectiveness and safety of antiobesity drugs in clinical populations of children and adolescents is needed.